TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8156285
Drug: Hydroxychloroquine tablet
Normalized name: hydroxychloroquine Oral Tablet
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxychloroquine tablet (155 mg)
Study: 17380263
Drug: Body mass
Normalized name: Total Body Massager Item
Approvals — FDA: no, EMA: no, PMDA: no
Description: Body mass index (BMI) and injection site
Study: 8072258
Drug: Cyclosporin A
Normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin A (CsA) at a dosage of 5.54 ± 0.81 mg/kg/day for 12 to 60 months
Study: 23676253
Drug: 40 IU
Normalized name: Oxytocin 40 IU/1 ML Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 IU intranasal oxytocin
Study: 19547811
Drug: bromazepam 6
Normalized name: bromazepam 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: bromazepam 6 mg
Study: 10207807
Drug: Interferon therapy
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon therapy
Study: 20034440
Drug: Conventional needle
Normalized name: NEEDLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional needle injection acupuncture
Study: 27776149
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg caffeine
Study: 14736293
Drug: Hill-climbing heuristic
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hill-climbing heuristic applied to the 6-coin problem with a concrete and visualizable solution
Study: 24535134
Drug: IFNβ-1a IM
Normalized name: PEG IFN-beta-1a
DrugBank: Peginterferon beta-1a (DB09122)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IFNβ-1a IM 30 μg once-weekly
Study: 29081664
Drug: everolimus 10
Normalized name: everolimus 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: everolimus 10 mg/day
Study: 16569807
Drug: Atenolol-based hypertension
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atenolol-based hypertension treatment
Study: 21314440
Drug: Oral combination
Normalized name: clozapine ORAL COMBINATION PACKAGE (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral combination of desmin (300 mg/day) and troxerutin (300 mg/day) with Centella asiatica (30 mg/day) and Melilotus (160 mg/day) for 14 months
Study: 2860283
Drug: Temazepam 20
Normalized name: temazepam 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temazepam 20 mg in soft gelatine capsule
Study: 11408210
Drug: Isoniazid (INH)
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoniazid (INH) 5 mg/kg daily
Study: 11408210
Drug: Isoniazid (INH)
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoniazid (INH) 5 mg/kg daily and 25 mg of rifalazil once weekly
Study: 9495409
Drug: 0.025 mg
Normalized name: lisuride 0.025 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.025 mg intrathecal morphine plus 75 mg i.m. diclofenac every 8 h
Study: 30981162
Drug: Guided internet-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided internet-based cognitive behavioural therapy (ICBT)
Study: 12657911
Drug: Racemic reboxetine
Normalized name: REBOXETINE
DrugBank: Reboxetine (DB00234)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Racemic reboxetine (therapeutic drug monitoring)
Study: 11084270
Drug: Ketorolac tromethamine
Normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketorolac tromethamine 0.5% administered 30 minutes preoperatively
Study: 1869364
Drug: Albendazole 1200
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Albendazole 1200 mg x 3 days
Study: 30622317
Drug: Irbesartan 150
Normalized name: irbesartan 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan 150 mg
Study: 17356554
Drug: Probiotic capsules
Normalized name: Quad-Probiotic Capsules
DrugBank: Bifidobacterium longum (DB19248)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic capsules (3 capsules daily containing 10^9 CFU Lactobacillus acidophilus and Bifidobacterium longum, 10-15 mg fructo-oligosaccharide)
Study: 9732168
Drug: Topical calcipotriol
Normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical calcipotriol (50 microgram/g) applied twice daily
Study: 7995005
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg ordinary-release theophylline
Study: 25001663
Drug: Nutraceutical combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutraceutical combination (red yeast rice, Silybum marianum, octasonol)
Study: 14647955
Drug: Active priming
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active priming injection of cocaine (0, 15 or 30 mg/70 kg)
Study: 10552188
Drug: tedisamil 100
Normalized name: tedisamil
DrugBank: Tedisamil (DB06200)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tedisamil 100 mg b.i.d.
Study: 1696662
Drug: atenolol 50
Normalized name: atenolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: atenolol 50 mg b.i.d.
Study: 29070709
Drug: HP-BEEF diet
Normalized name: Beef
DrugBank: Beef (DB10509)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HP-BEEF diet (124 g protein/d; 60% from beef, 40% from plant sources)
Study: 17112693
Drug: Ibuprofen 1200
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen 1200 mg/day
Study: 28744857
Drug: Pre-operative intravenous
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pre-operative intravenous methylprednisolone 125 mg
Study: 8600742
Drug: Repair with
Normalized name: AVOBENZONE 30 mg in 1 g / OCTINOXATE 75 mg in 1 g / OCTISALATE 50 mg in 1 g TOPICAL CREAM [Exuviance Age Reverse Day Repair with Sunscreen Broad Spectrum SPF 30]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repair with synthetic augmentation
Study: 25925875
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba (80-120 mg/day)
Study: 17898337
Drug: Lowering the
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lowering the dosages of antiparkinsonian medications
Study: 10396191
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of 5‐isosorbide mononitrate (ISMO)
Study: 346315
Drug: Halcinonide solution
Normalized name: Halcinonide
DrugBank: Halcinonide (DB06786)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Halcinonide solution (0.1%)
Study: 15536460
Drug: Oral ALF
Normalized name: ALF component monophosphoryl lipid A
DrugBank: Monophosphoryl lipid A (DB19290)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ALF after rifampin
Study: 15536460
Drug: Oral ALF
Normalized name: ALF component monophosphoryl lipid A
DrugBank: Monophosphoryl lipid A (DB19290)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ALF after troleandomycin (TAO)
Study: 15536460
Drug: Oral ALF
Normalized name: ALF component monophosphoryl lipid A
DrugBank: Monophosphoryl lipid A (DB19290)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ALF after grapefruit juice
Study: 9493975
Drug: Control arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control arm (no adjuvant therapy)
Study: 18256460
Drug: Formulation containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation containing ziyuglycoside I
Study: 22642182
Drug: 15-session crafts
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 15-session crafts program or no treatment
Study: 2440626
Drug: Cisplatinum treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatinum treatment
Study: 2440626
Drug: Cisplatinum treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatinum treatment in advanced previously untreated disease
Study: 9230825
Drug: Physostigmine salicylate
Normalized name: PHYSOSTIGMINE SALICYLATE
DrugBank: Physostigmine (DB00981)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physostigmine salicylate (8 mg/mL)
Study: 26703279
Drug: Sustained-release dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sustained-release dexamethasone
Study: 4014796
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg ergometrine by slow intravenous injection
Study: 30086408
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin (OXT)
Study: 8778603
Drug: sodium benzoate,
Normalized name: Sodium Benzoate, Powder, NF
Approvals — FDA: no, EMA: no, PMDA: no
Description: sodium benzoate, alone or in combination with sodium phenylacetate or sodium phenylbutyrate, or sodium phenylbutyrate alone
Study: 8778603
Drug: drugs that
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: drugs that activate new pathways of waste‐nitrogen excretion
Study: 2144797
Drug: Atrial natriuretic
Normalized name: Atrial natriuretic factor
DrugBank: Atrial natriuretic peptide (DB15591)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrial natriuretic factor (ANF) infusion (50 ng/kg/min)
Study: 20705215
Drug: Serotonin noradrenaline
Normalized name: serotonin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serotonin noradrenaline reuptake inhibitors
Study: 10565463
Drug: CSF glycine
Normalized name: Glycine
DrugBank: Glycine (DB00145)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CSF glycine levels in newborns with moderate HIE (19.1 micromol/l)
Study: 10565463
Drug: CSF glycine
Normalized name: Glycine
DrugBank: Glycine (DB00145)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CSF glycine levels in control group (12.08 micromol/l)
Study: 2899773
Drug: Alternative therapies
Normalized name: HERBS/ALTERNATIVE THERAPIES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternative therapies usually prescribed in France
Study: 24814037
Drug: 3g red
Normalized name: Red gum
DrugBank: Eucalyptus gum (DB15537)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3g red ginseng daily for 12 weeks
Study: 26879784
Drug: Quadruple regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadruple regimen (rabeprazole + amoxicillin + clarithromycin + bismuth potassium citrate) for 10 days followed by bismuth-placebo for 21 days (Group A1)
Study: 23542218
Drug: Constraint-Induced Movement
Normalized name: constant albicans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constraint-Induced Movement Therapy (CIMT-D) administered 15 to 21 months poststroke
Study: 17181922
Drug: Sham HT
Normalized name: 5-HT
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham HT administered for 40 minutes daily for 5 days per week for two weeks
Study: 18820977
Drug: Oral polyethylene
Normalized name: polyethylenes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral polyethylene glycol (Group A)
Study: 12131185
Drug: IL-2 plus
Normalized name: IL-2
DrugBank: Human interleukin-2 (DB14865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-2 plus HAART (9 megaunits daily for 5 days in 6-week intervals for a total of eight cycles)
Study: 3964332
Drug: Preparation A
Normalized name: POVIDONE-IODINE 75 mg in 1 mL TOPICAL SOLUTION [Antiseptic Patient Preoperative Skin Preparation and Surgical Hand Scrub]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation A (hard gelatine capsule with pellets)
Study: 22652990
Drug: Caudal epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal epidural injections of local anesthetic (lidocaine 0.5%)
Study: 27729766
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg ALA
Study: 7721409
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of enalapril and candoxatrilat
Study: 1959863
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg ursodeoxycholic acid alone (group A)
Study: 1959863
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 500 mg ursodeoxycholic acid and 500 mg chenodeoxycholic acid (group B)
Study: 25928772
Drug: Daily cell
Normalized name: AVOBENZONE 30 mg in 1 g / HOMOSALATE 100 mg in 1 g / OCTISALATE 50 mg in 1 g / OCTOCRYLENE 10 mg in 1 g / OXYBENZONE 50 mg in 1 g TOPICAL CREAM [ReVive Sensitif Renewal Daily Cellular Protection Broad Spectrum SPF 30 Sunscreen]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily cell phone support intervention
Study: 19996415
Drug: Intracoronary infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary infusion of bone marrow-derived progenitor cells (BMC)
Study: 22471392
Drug: Atenolol 75
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atenolol 75 mg for 4 weeks
Study: 15681624
Drug: Testosterone gel
Normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone gel 1% (5 g applied once a day)
Study: 17066085
Drug: Perindopril 4
Normalized name: perindopril 4 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril 4 mg + Indapamide 1.25 mg
Study: 2806927
Drug: levodopa administration
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: levodopa administration
Study: 15189916
Drug: Influenza vaccination
Normalized name: Haemophilus influenzae b (Ross strain) capsular polysaccharide meningococcal protein conjugate vaccine Injection [PedvaxHIB]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Influenza vaccination (purified, trivalent, split-virus vaccine)
Study: 15704358
Drug: Penicillin V
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin V (50,000 IU/kg, divided in three doses for 10 days)
Study: 27548030
Drug: Modular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modular treatment (MATCH)
Study: 21178605
Drug: Preemptive thoracic
Normalized name: Thoracol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preemptive thoracic epidural analgesia without ketamine (0.12% levobupivacaine, 2 μg/mL of fentanyl, total volume of 500 mL)
Study: 21178605
Drug: Preemptive low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Preemptive low-dose epidural ketamine
Study: 24149855
Drug: Negative pressure
Normalized name: DRESSING,NEGATIVE PRESSURE WOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative pressure wound therapy (NPWT) combined with dynamic fascial sutures (DFS)
Study: 9226591
Drug: Rifampicin 1200
Normalized name: Rifampicine
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampicin 1200 mg
Study: 11874927
Drug: Buffered Regular
Normalized name: INSULIN,REGULAR,HUMAN BUFFERED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buffered Regular Insulin (BR)
Study: 7851193
Drug: Controlled-release mesalamine
Normalized name: mesalamine Delayed Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release mesalamine at 4 g/day for 12 months
Study: 9034984
Drug: Meloxicam 15
Normalized name: meloxicam 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meloxicam 15 mg once daily
Study: 3287907
Drug: Piroxicam 20
Normalized name: piroxicam 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam 20 mg
Study: 6437268
Drug: Intramuscular piritramide
Normalized name: piritramide
DrugBank: Piritramide (DB12492)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular piritramide
Study: 21173411
Drug: Unblinded echinacea
Normalized name: Echinacea
DrugBank: Echinacea (DB14240)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unblinded echinacea pills (10.2 g during the first 24 hours and 5.1 g during each of the next 4 days)
Study: 9671427
Drug: Betaxolol hydrochloride
Normalized name: Betaxolol Hydrochloride
DrugBank: Betaxolol (DB00195)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betaxolol hydrochloride 0.50% (Betoptic) administered to 15 POAG and 7 NTG eyes
Study: 29107562
Drug: Delayed switch
Normalized name: Witch Hazel
DrugBank: Witch hazel (DB11111)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed switch to Dolutegravir monotherapy
Study: 3521859
Drug: Cimetropium bromide
Normalized name: cimetropium bromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetropium bromide (50 mg BID)
Study: 22156542
Drug: Untreated control
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Untreated control (UC) group at 67 μg/kg/day
Study: 17827633
Drug: Initial antithrombin
Normalized name: antithrombin III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial antithrombin (AT) levels at 15 mg/dL
Study: 22098676
Drug: Inactivated influenza
Normalized name: influenza, inactivated, whole virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated influenza vaccine
Study: 3137888
Drug: Tegafur 400
Normalized name: tegafur
DrugBank: Tegafur (DB09256)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Tegafur 400 mg/m2 alone (Group A)
Study: 11841196
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate (BDP) 5 mg/d
Study: 7526028
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with ifosfamide, cisplatin, and adriamycin
Study: 30660609
Drug: Nivolumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab plus ipilimumab (Nivolumab 3 mg/kg every 2 weeks + Ipilimumab 1 mg/kg every 6 weeks)
Study: 21663652
Drug: CBPR walking
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CBPR walking intervention with social support walking groups, pedometer diary self-monitoring, monthly diet and physical activity education sessions, and individualized motivational interviewing sessions.
Study: 9915282
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of dialysis (target eKt/V 1.45)
Study: 29590422
Drug: Access to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Access to non-pharmacologic treatments
Study: 3160356
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of atenolol and nitrendipine (100 mg and 20 mg respectively, once daily)
Study: 10733492
Drug: Chemotherapy (CTx)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (CTx)
Study: 20301996
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of vancomycin (15 mg/kg loading dose for 1 h followed by 30 mg/kg continuous infusion over 24 h for 48 h)
Study: 20301996
Drug: Intermittent infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent infusion of vancomycin (15 mg/kg for 1 h every 12 h for 48 h)
Study: 19149880
Drug: Active Physical
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Physical Therapy (APT)
Study: 25223731
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg selisistat
Study: 12589529
Drug: Bovine surfactant
Normalized name: Pegademase Bovine
DrugBank: Pegademase (DB00061)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bovine surfactant (100 mg/kg intratracheally under continuous ventilation and PEEP)
Study: 10625850
Drug: Benzydamine hydrochloride
Normalized name: benzydamine hydrochloride
DrugBank: Benzydamine (DB09084)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzydamine hydrochloride 0.15% oral mouthwash 3 times a day for 4 weeks
Study: 1942288
Drug: Pinacidil 25
Normalized name: pinacidil 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pinacidil 25 mg per day
Study: 7863474
Drug: Olive oil
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive oil (4 x 1 g capsules, placebo)
Study: 16173137
Drug: PYY infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PYY infusion
Study: 10823256
Drug: Fixed dose
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dose subcutaneous LMWH Certoparin (8,000 anti-factor Xa U b.i.d.)
Study: 11408793
Drug: DA agonist
Normalized name: DAS-181
DrugBank: DAS-181 (DB15313)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DA agonist (lisuride 0.2 mg)
Study: 27373088
Drug: Budesonide treatment
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide treatment
Study: 23985625
Drug: Peramivir 300
Normalized name: Peramivir
DrugBank: Peramivir (DB06614)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Peramivir 300 mg twice daily
Study: 8291866
Drug: Intravesical chemotherapy
Normalized name: Valrubicin Intravesical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical chemotherapy with doxorubicin (ADM)
Study: 8291866
Drug: Intravesical chemotherapy
Normalized name: Valrubicin Intravesical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical chemotherapy with mitomycin C (MMC)
Study: 8291866
Drug: Intravesical immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical immunotherapy with bacillus Calmette-Guérin (BCG)
Study: 9181646
Drug: Alternating treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternating treatment with zidovudine 600 mg/day and didanosine 400 mg/day
Study: 6396120
Drug: Clotrimazole applied
Normalized name: Clotrimazole
DrugBank: Clotrimazole (DB00257)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clotrimazole applied twice daily
Study: 30632413
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein isolate (0.5 g·kg‐1·day‐1)